Work Here?
Superluminal Medicines
Work Here?
ML-driven design of candidate small molecules
Superluminal Medicines
Work Here?
ML-driven design of candidate small molecules
Overview
Superluminal Medicines develops small-molecule drug discovery solutions by combining deep biology, chemistry, and machine learning. It creates candidate-ready compounds with high speed and accuracy, using a proprietary big data platform and predictive design models to model protein shapes and design selective compounds that induce precise structural changes for therapeutic effects. The company collaborates with pharmaceutical and biotech firms, licensing its technology and pursuing milestone-based payments, rather than selling products outright. This partnership-centric model helps clients accelerate their drug discovery programs in a highly competitive market. The company aims to shorten the path from target to clinical candidate by delivering well-characterized, selective small molecules efficiently.
About Superluminal Medicines
Industries
Data & Analytics
AI & Machine Learning
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series A
Total Funding
$153M
Headquarters
Boston, Massachusetts
Founded
2023
Get referred to Superluminal Medicines
See people who can refer or advise you
Simplify's Take
What believers are saying
- Lilly's February 2026 update reaffirmed up to $1.3B in payments.
- Superluminal expects an IND submission in late 2026 for obesity.
- RA Capital, Insight, NVentures, Catalio, and Lilly funded the $120M Series A.
What critics are saying
- Lilly gets exclusive rights, so Superluminal loses downstream economics.
- The lead obesity asset still needs 2026 human data after IND filing.
- A failed MC4R program would crush platform credibility and future partnering.
What makes Superluminal Medicines unique
- Superluminal combines protein dynamics, structural biology, and ML on GPCRs.
- Lilly backed the 2024 Series A and signed a 2025 $1.3B pact.
- Its lead MC4R obesity program entered IND-enabling studies in July 2025.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$153M
Above
Industry Average
Funded Over
2 Rounds
Insight PartnersIndustry standards
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Flexible Work Hours
Hybrid Work Options
Remote Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
Sabbatical Leave
Wellness Program
Mental Health Support
Gym Membership
Conference Attendance Budget
Professional Development Budget
Stock Options
Company Equity
401(k) Retirement Plan
401(k) Company Match
Phone/Internet Stipend
Home Office Stipend
Family Planning Benefits
Fertility Treatment Support
Adoption Assistance
Parental Leave
Relocation Assistance
Employee Referral Bonus
Tuition Reimbursement
Professional Certification Support
Mentorship Program
Training Programs
Tuition Reimbursement
Meal Benefits
Commuter Benefits
Pet Insurance
Legal Services
Employee Discounts
Company Social Events
Growth & Insights and Company News
6 month growth
↑ 31%1 year growth
↑ 31%2 year growth
↑ 31%Eli Lilly (NYSE: LLY) has entered into a collaboration with Boston-based Superluminal Medicines to develop small-molecule therapies for undisclosed G protein-coupled receptor (GPCR) targets linked to cardiometabolic diseases and obesity.
Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G protein-coupled receptor biotech. | Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G protein-coupled receptor biotech.
Superluminal Medicines Inc. has entered a collaboration with Eli Lilly and Co. in a deal worth up to $1.3 billion. The partnership aims to develop therapies for cardiometabolic diseases and obesity by targeting undisclosed G protein-coupled receptors. The deal includes up-front and near-term investments, an equity investment, development and commercial milestones, and tiered royalties on net sales.
Superluminal Medicines Inc. and Eli Lilly and Co. are collaborating in a deal to develop cardiometabolic disease and obesity therapies by aiming at undisclosed G protein-coupled receptor targets.
Superluminal Medicines, a Boston, MA-based company that uses generative biology, chemistry and machine learning approaches to create medicines, raised $120M in Series A funding
Superluminal Medicines is Hiring for 9 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Superluminal Medicines
Industries
Data & Analytics
AI & Machine Learning
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series A
Total Funding
$153M
Headquarters
Boston, Massachusetts
Founded
2023
Superluminal Medicines is Hiring for 9 Jobs on Simplify!
Find jobs on Simplify and start your career today